Pharming and transgenic plants.
Plant represented the essence of pharmacopoeia until the beginning of the 19th century when plant-derived pharmaceuticals were partly supplanted by drugs produced by the industrial methods of chemical synthesis. In the last decades, genetic engineering has offered an alternative to chemical synthesis, using bacteria, yeasts and animal cells as factories for the production of therapeutic proteins. More recently, molecular farming has rapidly pushed towards plants among the major players in recombinant protein production systems. Indeed, therapeutic protein production is safe and extremely cost-effective in plants. Unlike microbial fermentation, plants are capable of carrying out post-translational modifications and, unlike production systems based on mammalian cell cultures, plants are devoid of human infective viruses and prions. Furthermore, a large panel of strategies and new plant expression systems are currently developed to improve the plant-made pharmaceutical's yields and quality. Recent advances in the control of post-translational maturations in transgenic plants will allow them, in the near future, to perform human-like maturations on recombinant proteins and, hence, make plant expression systems suitable alternatives to animal cell factories.
Liénard
David
D
Université de Rouen, CNRS UMR 6037, IFRMP 23, GDR 2590, Faculté des Sciences, Bât. Ext. Biologie, 76821 Mont-Saint-Aignan cedex, France.
Sourrouille
Christophe
C
Gomord
Véronique
V
Faye
Loïc
L
D000383:Agriculture / Q000639:trends*; D004345:Drug Industry / Q000639:trends; D010940:Plant Proteins / Q000502:physiology* / Q000627:therapeutic use*; D030821:Plants, Genetically Modified / Q000378:metabolism*; D015202:Protein Engineering / Q000379:methods*; D011994:Recombinant Proteins / Q000378:metabolism* / Q000627:therapeutic use*
D010940:Plant Proteins; D011994:Recombinant Proteins